S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo

AbbVie (ABBV) Stock Price, News & Analysis

$166.41
+1.75 (+1.06%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$163.25
$166.60
50-Day Range
$161.67
$182.10
52-Week Range
$130.96
$182.89
Volume
5.53 million shs
Average Volume
5.64 million shs
Market Capitalization
$294.65 billion
P/E Ratio
60.96
Dividend Yield
3.73%
Price Target
$177.43

AbbVie MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.77 Rating Score
Upside/​Downside
6.6% Upside
$177.43 Price Target
Short Interest
Healthy
0.74% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.35mentions of AbbVie in the last 14 days
Based on 45 Articles This Week
Insider Trading
Selling Shares
$67.78 M Sold Last Quarter
Proj. Earnings Growth
8.78%
From $11.16 to $12.14 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.89 out of 5 stars

Medical Sector

22nd out of 907 stocks

Pharmaceutical Preparations Industry

7th out of 417 stocks

ABBV stock logo

About AbbVie Stock (NYSE:ABBV)

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

ABBV Stock Price History

ABBV Stock News Headlines

Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer (ABBV)
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.
Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
AbbVie (NYSE:ABBV) Trading 0.2% Higher
Wells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV)
Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
AbbVie (ABBV) to Release Earnings on Friday
AbbVie: Through Humira's Crisis Towards Solid Growth
See More Headlines
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/15 Dividend
1/12/2024
Last Earnings
2/02/2024
Dividend Payable
2/15/2024
Ex-Dividend for 5/15 Dividend
4/12/2024
Today
4/21/2024
Next Earnings (Confirmed)
4/26/2024
Dividend Payable
5/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
00287Y10
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$177.43
High Stock Price Target
$196.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+6.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

Net Income
$4.86 billion
Pretax Margin
11.51%

Debt

Sales & Book Value

Annual Sales
$54.32 billion
Cash Flow
$15.82 per share
Book Value
$5.78 per share

Miscellaneous

Outstanding Shares
1,770,650,000
Free Float
1,766,220,000
Market Cap
$294.65 billion
Optionable
Optionable
Beta
0.58

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in AbbVie:

  • AbbVie offers a diverse range of pharmaceutical products, including innovative treatments like Skyrizi and Rinvoq, which have shown promising results in treating various diseases.
  • The company has a strong pipeline of drugs in development, indicating potential for future growth and revenue generation.
  • AbbVie's collaboration with reputable companies like Janssen Biotech and Genentech for developing biologics showcases its commitment to innovation and expanding its product portfolio.
  • Recent positive developments in AbbVie's financial performance, coupled with a stable dividend payout, make it an attractive option for income-seeking investors.
  • Considering the current stock price and market trends, AbbVie's stock shows potential for capital appreciation in the near future.

Cons

Investors should be bearish about investing in AbbVie for these reasons:

  • AbbVie faces risks associated with patent expirations of key drugs, which could lead to revenue declines and increased competition from generic alternatives.
  • The pharmaceutical industry is highly regulated, and any changes in regulations or unexpected legal challenges could impact AbbVie's operations and financial performance.
  • Concerns about the potential impact of healthcare reforms or changes in reimbursement policies on AbbVie's profitability may pose risks to investors.
  • Market volatility and macroeconomic factors could affect AbbVie's stock price, leading to fluctuations in investor returns.
  • Investors should carefully monitor any developments related to AbbVie's ongoing legal disputes or regulatory investigations, as these could have negative implications on the company's reputation and financial standing.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

ABBV Stock Analysis - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABBV shares.
View ABBV analyst ratings
or view top-rated stocks.

What is AbbVie's stock price target for 2024?

13 brokerages have issued twelve-month target prices for AbbVie's stock. Their ABBV share price targets range from $150.00 to $196.00. On average, they anticipate the company's stock price to reach $177.43 in the next year. This suggests a possible upside of 6.6% from the stock's current price.
View analysts price targets for ABBV
or view top-rated stocks among Wall Street analysts.

How have ABBV shares performed in 2024?

AbbVie's stock was trading at $154.97 on January 1st, 2024. Since then, ABBV stock has increased by 7.4% and is now trading at $166.41.
View the best growth stocks for 2024 here
.

Are investors shorting AbbVie?

AbbVie saw a decline in short interest in March. As of March 31st, there was short interest totaling 13,120,000 shares, a decline of 10.7% from the March 15th total of 14,690,000 shares. Based on an average daily trading volume, of 5,660,000 shares, the days-to-cover ratio is presently 2.3 days.
View AbbVie's Short Interest
.

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our ABBV earnings forecast
.

How can I listen to AbbVie's earnings call?

AbbVie will be holding an earnings conference call on Friday, April 26th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) announced its quarterly earnings results on Friday, February, 2nd. The company reported $2.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.76 by $0.03. The company had revenue of $14.30 billion for the quarter, compared to analysts' expectations of $14.02 billion. AbbVie had a trailing twelve-month return on equity of 162.28% and a net margin of 8.95%. The company's revenue for the quarter was down 5.4% compared to the same quarter last year. During the same quarter last year, the company posted $3.60 EPS.
Read the conference call transcript
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Thursday, February 15th. Stockholders of record on Monday, April 15th will be paid a dividend of $1.55 per share on Wednesday, May 15th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.73%. The ex-dividend date of this dividend is Friday, April 12th.
Read our dividend analysis for ABBV
.

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $6.20 per share and currently has a dividend yield of 3.73%. The company has been increasing its dividend for 52 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 227.11%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 51.07% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY 2024 earnings guidance on Wednesday, April, 3rd. The company provided EPS guidance of 10.970-11.170 for the period, compared to the consensus earnings per share estimate of 11.190. The company issued revenue guidance of -.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?
Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.25%), Guinness Asset Management LTD (0.07%), Global Assets Advisory LLC (0.05%), Ferguson Wellman Capital Management Inc. (0.04%), Everett Harris & Co. CA (0.03%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Kevin K Buckbee, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents and Timothy J Richmond.
View institutional ownership trends
.

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AbbVie have any subsidiaries?
The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More
This page (NYSE:ABBV) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners